Neuropathic pain Chemotherapy-induced peripheral neuropathy (CIPN)

Background information: Repeated administration in rodents of commonly used chemotherapeutic agents, such as platinum derivatives and vinca alkaloids, reproduces many of the pathological mechanisms associated with human CIPN, supporting the utility of these experimental models for mechanistic studies of peripheral neuropathy induced chemotherapy treatment and for the screening of novel analgesic compounds. CIPN is manifested in rodents by robust and long-lasting referred pain (hypersensitivity to acute application of noxious (hyperalgesia) and non-noxious (allodynia) stimuli in the animal hind paws.

Animals: SD rats (vincristine model), Wistar rats (oxaliplatin model).

Efficacy test: The efficacy of systemic administered drugs can be evaluated after acute administration during the period of stable allodynia (approximately during 1 or 2 weeks after finishing the administration of chemotherapeutic agent) (acute analgesic effect), or after repeated treatment in a preventive protocol (disease-modifying effect). Efficacy evaluation of drug combinations is also possible, including isobolographic analysis of the interaction.

Assessments: Mechanical allodynia is evaluated by measuring hind paw withdrawal threshold (g) in response to mechanical (von Frey test) stimulation. Additional readouts can also be evaluated (i.e., cold allodynia) (not validated).

Positive control: Pregabalin (acute analgesic efficacy)

Criteria for significance: ANOVA followed by Tukey’s test is applied for comparison between the vehicle and treatment groups. Significant activity is considered at the P<0.05 level.

Turnaround time: xx Days.

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS